Biotech, Hepatitis C, clinical trials
Zymo Drug Kills Hep C Virus
Luke Timmerman 4/24/09
ZymoGenetics (NASDAQ: ZGEN), a Seattle biotech company, and partner Bristol-Myers Squibb said today that a drug they are co-developing for hepatitis C was able to kill the virus with minimal side effects in a small four-week study. The trial looked at pegylated interferon lambda on its own, or in combination with a standard ribavirin treatment. The full data was presented at the European Association for the Study of the Liver meeting in Copenhagen, Denmark.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
5/13/09 10:55 pm
help me
7/5/09 5:24 pm
I do hope this treatment works and it’s on the market soon. The side effects
of current treatment of pegintron nearly killed my wife.